Our specialists regularly oversee clinical research studies in an effort to contribute to the important area of women's healthcare. Through our research opportunities at NorthShore, we strive to provide our patients with access to leading edge treatment options not widely available elsewhere. 

The following studies are open to enrollment. If we are interested in learning more, please ask your physician, nurse or other care team member.

Gynecological Pain and Minimally Invasive Surgery Clinical Trials

Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain (Chronic Pain Risk Associated with Menstrual Period Pain–CRAMPP)
Aims: The purpose of this study is to determine if some women with dysmenorrhea (painful periods) are at higher future risk of developing chronic pelvic pain (CPP) and if oral contraceptives (OC) can be used to reverse this chronic pain risk.
Diagnoses: Interstitial Cystitis/Painful Bladder Syndrome, Dysmenorrhea (painful periods), Migraine or Healthy Controls
Principal Investigator: Frank Tu, MD, MPH
IRB Approval Number: EH 13-094
Sponsor:NIH/NIDDK
Contact: Interested participants should contact Julia Kane at 847.570.2622.
Open to Enrollment: Yes

Novel Approaches to Investigation of Menstrual Pain
Aims: The purpose of this study is to find out how contractions of the uterus cause menstrual pain. Specifically, we want to find out if women with more pain have more electrical and muscle activity in abdominal tissue than healthy controls. We will also see how the nervous system responds (heart and respiratory rate). The study involves one 4-hour session during the participants menstrual period.
Diagnosis: Dysmenorrhea (painful periods)
Principal Investigator: Kevin Hellman, PhD
IRB Approval Number: EH11-210
Sponsor: NorthShore University HealthSystem  
Contact: Interested participants should contact Kat Dillane at 847.570.4903.
Open to Enrollment:  Yes

Urogynecology Clinical Trials

Bladder Capacity as an Objective Measure of Response to Intravesical Treatment of Newly Diagnosed Interstitial Cystitis: a Prospective Randomized Trial
Aim: The purpose of this study is to determine whether a change in the volume of water that a woman can hold in her bladder can be used to determine whether treatment for interstitial cystitis, dimethyl sulfoxide and triamcinolone or bupivicaine/ heparin/triamcinolone mixture, is working.
Principal Investigator: Peter K. Sand, MD
IRB Approval Number: EH11-081
Contact: call 224.251.3493 with questions regarding the study.

A Prospective, Non-Randomized, Parallel Cohort, Multi-center Study of Uphold LITE vs. Native Tissue for the Treatment of Women with Anterior/Apical Pelvic Organ Prolapse
Aim: The purpose of this research study is to compare two different standard of care treatments: a device (Uphold LITE) to a native tissue repair procedure for the treatment of symptoms for pelvic organ prolapse. Safety information and patient outcomes will be collected for three years and evaluated.
Principal Investigator: Peter K. Sand, MD
IRB Approval Number: EH13-301
Contact: call 224.251.3493 with questions regarding the study.

A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence
Aim: The purpose of this study is to evaluate the safety and efficacy of a medical procedure in which your own muscle cells (AMDC-USR) are collected, processed, and then re-injected into the tissues of your urinary passage. This study will determine if the cells are safe and effective in treating stress urinary incontinence in females.
Principal Investigator: Peter K. Sand, MD
IRB Approval Number: EH13-455
Contact: call 224.251.3493 with questions regarding the study.

A Fidelity Measure for Pelvic Floor Physical Therapy in Female Pelvic Pain: A Validation Study
Aim: The purpose of this research study is to quantify the essential components of a pelvic floor physical therapy session and to determine the effect of adherence to a standard study protocol on patient reported outcomes of improvement.
Principal Investigator: Urogynecology f
IRB Approval Number: EH15-282
Contact: call 224.251.2374 with questions regarding the study.

The Risk of Cognitive Impairment in Patients Starting Anticholinergic Medication to Treat Overactive Bladder: A Prospective Trial
Aim: With this study, we plan to describe the risk of cognitive decline in patients starting treatment with anticholingeric medications for overactive bladder.
Principal Investigator: Roger Goldberg, MD
IRB Approval Number: EH16-059
Contact: call 224.251.2374 with questions regarding the study.